Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
But will the FDA accept the surrogate endpoint used in ASC4First?
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.